Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)

• Elisa Waldmann,

  Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – review & editing

  Affiliation Medical Department IV, LMU Klinikum Grosshadern, Munich, Germany

  ⨯
• Liya Wu,

  Roles Data curation, Investigation, Writing – review & editing

  Current address: Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany

  Affiliation Medical Department IV, LMU Klinikum Grosshadern, Munich, Germany

  ⨯
• Kristina Busygina,

  Roles Data curation, Investigation, Writing – review & editing

  Affiliation Medical Department IV, LMU Klinikum Grosshadern, Munich, Germany

  ⨯
• Julia Altenhofer,

  Roles Data curation, Investigation, Methodology, Writing – review & editing

  Affiliation Medical Department IV, LMU Klinikum Grosshadern, Munich, Germany

  ⨯
• Kerstin Henze,

  Roles Data curation, Investigation, Methodology

  Affiliation Medical Department IV, LMU Klinikum Grosshadern, Munich, Germany

  ⨯
• Alexander Folwaczny,

  Roles Investigation, Validation, Writing – review & editing

  Affiliation Medical Department IV, LMU Klinikum Grosshadern, Munich, Germany

  ⨯
• Klaus G. Parhofer

  Roles Conceptualization, Data curation, Formal analysis, Methodology, Resources, Supervision, Validation, Writing – original draft, Writing – review & editing

  * E-mail: klaus.parhofer@med.uni-muenchen.de

  Affiliation Medical Department IV, LMU Klinikum Grosshadern, Munich, Germany

  https://orcid.org/0000-0001-9873-0412

  ⨯